These results indicate the prognostic value of baseline anemia in patients with NSCLC with EGFR mutations, thus highlighting the importance of the early treatment of anemia and the control of Hb levels in cancer patients, and suggesting that improving the management of anemia may also prolong patient survival. This evidence concerns the gene GSTM1 and cancer.